{"denoms":[{"counts":[{"groupId":"BG000","value":"75"}],"units":"Participants"}],"groups":[{"description":"Participants received romiplostim administered weekly by subcutaneous injection during the 12-month treatment period. The starting dose was 1 μg/kg with weekly dose increases in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg to reach a target platelet count of ≥ 50 x 10\\^9/L. At the completion of the 12-month treatment period, participants receiving only romiplostim and with a platelet count ≥ 50 x 10\\^9/L entered the tapering period, during which the romiplostim dose was decreased by 1 µg/kg every 2 weeks, for up to 19 weeks. Participants who had tapered off treatment with romiplostim and whose platelet count dropped below 50 x 10\\^9/L could reinitiate romiplostim for up to 8 weeks.","id":"BG000","title":"Romiplostim"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"18.7","value":"44.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"31"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Black (or African American)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"72"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Unknown"}],"paramType":"NUMBER","title":"Race","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Hispanic/Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"69"}]}],"title":"Not Hispanic/Latino"}],"paramType":"NUMBER","title":"Ethnicity","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.1","upperLimit":"6.6","value":"2.2"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time since ITP diagnosis","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"15.80","value":"19.78"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Platelet Count at Screening","unitOfMeasure":"x 10^9/L"}]}